Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 24, 2026

Geely Technology Ecosystem on Full Display and Debut of China’s First Purpose-Built Robotaxi at Auto China 2026

View original at finance.yahoo.com
Geely Technology Ecosystem on Full Display and Debut of China’s First Purpose-Built Robotaxi at Auto China 2026 BEIJING, April 24, 2026 (GLOBE NEWSWIRE) -- Geely Auto Group attended Auto China 2026 (Beijing Auto Show) for the first time directly as an exhibitor and showcased the group’s full technology ecosystem…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • EVA Cab is China's first purpose-built Robotaxi prototype

    60% confidence

  • The Quantum-Level AI Electronic and Electrical Architecture is the world's first

    60% confidence

  • Geely is the first global automaker to obtain the ISO 8800 AI Safety certification

    60% confidence

  • The 2160-line digital LiDAR system is the world's first

    60% confidence

  • SOVD technology is industry-first Service-Oriented Vehicle-Cloud Integrated Diagnostics

    60% confidence

  • EVA Cab demonstrates Geely's full entry into the Full-Domain AI 2.0 era

    60% confidence

  • EVA Cab features the industry's first mass-production-ready L4-level assisted driving software solution

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com